References
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982–3021. DOI: 10.1016/j.jacc.2020.11.010
- Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. 2009;61:1571–9. DOI: 10.1002/art.24836
- Atzeni F, Rodríguez-Carrio J, Popa CD, Nurmohamed MT, Szűcs G, Szekanecz Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:270–290. DOI: 10.1038/s41584-021-00593-3
- Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation, Aging, and Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79:837–847. DOI: 10.1016/j.jacc.2021.12.017
- Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49(2):295–307. DOI: 10.1093/rheumatology/kep366
- Luciano N, Barone E, Timilsina S, Gershwin ME, Selmi C. Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis. Clin Rev Allergy Immunol. 2023;65:403–419. DOI: 10.1007/s12016-023-08975-z
- Ljung L, Askling J, Rantapää-Dahlqvist S, Jacobsson L; ARTIS Study Group. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther. 2014;16(3):
R127 . DOI: 10.1186/ar4584 - Broch K, Anstensrud AK, Woxholt S, Sharma K, Tøllefsen IM, Bendz B, et al. Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021;77(15):1845–1855. DOI: 10.1016/j.jacc.2021.02.049
- Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:
k601 . DOI: 10.1136/bmj.k601 - Geurts S, Tilly MJ, Lu Z, Stricker BHC, Deckers JW, de Groot NMS, et al. Antihypertensive Drugs for the Prevention of Atrial Fibrillation: A Drug Target Mendelian Randomization Study. Hypertension. 2024;81(8):1766–1775. DOI: 10.1161/HYPERTENSIONAHA.123.21858
- Nolde M, Alayash Z, Reckelkamm SL, Kocher T, Ehmke B, Holtfreter B, et al. Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization study. Front Immunol. 2023;14:
1160148 . DOI: 10.3389/fimmu.2023.1160148 - Plebani M. Why C-reactive protein is one of the most requested tests in clinical laboratories? Clin Chem Lab Med. 2023;61(9):1540–1545. DOI: 10.1515/cclm-2023-0086
- Huang W, Xiao J, Ji J, Chen L. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. eLife. 2021;10:
e73873 . DOI: 10.7554/eLife.73873 - Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:
e1004383 . DOI: 10.1371/journal.pgen.1004383 - Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40:755–64. DOI: 10.1093/ije/dyr036
- Fu K, Si S, Jin X, Zhang Y, Duong V, Cai Q, et al. Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis. eBioMedicine. 2024;107:
105285 . DOI: 10.1016/j.ebiom.2024.105285 - Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. DOI: 10.1136/bmj.327.7414.557
- Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693–698. DOI: 10.1038/s41588-018-0099-7
- Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481–7. DOI: 10.1038/ng.3538
- Gerasimova EV, Popkova TV, Kirillova IG, Gerasimova DA, Nasonov EL, Lila AM. Interleukin-6: Cardiovascular Aspects of Long-Term Cytokine Suppression in Patients with Rheumatoid Arthritis. Int J Mol Sci. 2024;25:
12425 . DOI: 10.3390/ijms252212425 - Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813–8. DOI: 10.1136/annrheumdis-2015-207870
- Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499–3507. DOI: 10.1093/eurheartj/ehy310
- Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127–148. DOI: 10.1093/intimm/dxaa078
- Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124(2):315–327. DOI: 10.1161/CIRCRESAHA.118.313591
- Fomicheva OA, Popkova TV, Krougly LB, Gerasimova EV, Novikova DS, Pogorelova OA, et al. Factors of Progression and Occurrence of Atherosclerosis in Rheumatoid Arthritis. Kardiologiia. 2021;61(1):12–21. DOI: 10.18087/cardio.2021.1.n1331
- Bordy R, Totoson P, Prati C, Marie C, Wendling D, Demougeot C. Microvascular endothelial dysfunction in rheumatoid arthritis. Nat Rev Rheumatol. 2018;14(7):404–420. DOI: 10.1038/s41584-018-0022-8
- Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011;219(2):734–6. DOI: 10.1016/j.atherosclerosis.2011.09.015
- Bacchiega BC, Bacchiega AB, Usnayo MJ, Bedirian R, Singh G, Pinheiro GD. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Am Heart Assoc. 2017;6(3):
e005038 . DOI: 10.1161/JAHA.116.005038 - Henein MY, Vancheri S, Longo G, Vancheri F. The Role of Inflammation in Cardiovascular Disease. Int J Mol Sci. 2022;23(21):
12906 . DOI: 10.3390/ijms232112906 - Korantzopoulos P, Letsas KP, Tse G, Fragakis N, Goudis CA, Liu T. Inflammation and atrial fibrillation: A comprehensive review. J Arrhythm. 2018;34(4):394–401. DOI: 10.1002/joa3.12077
- Shitole SG, Heckbert SR, Marcus GM, Shah SJ, Sotoodehnia N, Walston JD, et al. Assessment of Inflammatory Biomarkers and Incident Atrial Fibrillation in Older Adults. J Am Heart Assoc. 2024;13(24):
e035710 . DOI: 10.1161/JAHA.124.035710 - Taniguchi K, Karin M. NF-B, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–324. DOI: 10.1038/nri.2017.142
- Alexanian M, Padmanabhan A, Nishino T, Travers JG, Ye L, Pelonero A, et al. Chromatin remodelling drives immune cell–fibroblast communication in heart failure. Nature. 2024;635(8038):434–443. DOI: 10.1038/s41586-024-08085-6
- Navarro HI, Daly AE, Rodriguez B, Wu S, Ngo KA, Fraser A, et al. NF-B RelB suppresses the inflammatory gene expression programs of dendritic cells by competing with RelA for binding to target gene promoters. Cell Discov. 2025 Feb 11;11(13). DOI: 10.1038/s41421-024-00767-9
- Mussbacher M, Salzmann M, Brostjan C, Hoesel B, Schoergenhofer C, Datler H, et al. Cell Type-Specific Roles of NF-B Linking Inflammation and Thrombosis. Front Immunol. 2019 Feb 4;10:
85 . DOI: 10.3389/fimmu.2019.00085 - Hui DY. Phospholipase A(2) enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol. 2012 Jun;23(3):235–240. DOI: 10.1097/MOL.0b013e328351b439
- Xiao L, Kirabo A, Wu J, Saleh MA, Zhu L, Wang F, et al. Renal Denervation Prevents Immune Cell Activation and Renal Inflammation in Angiotensin II-Induced Hypertension. Circ Res. 2015;117(6):547–57. DOI: 10.1161/CIRCRESAHA.115.306010
- Nguyen BA, Alexander MR, Harrison DG. Immune mechanisms in the pathophysiology of hypertension. Nat Rev Nephrol. 2024;20:530–540. DOI: 10.1038/s41581-024-00838-w
- Blaser MC, Bäck M, Lüscher TF, Aikawa E. Calcific aortic stenosis: omics-based target discovery and therapy development. Eur Heart J. 2025;46(7):620–634. DOI: 10.1093/eurheartj/ehae829
- Larsson SC, Butterworth AS, Burgess S. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J. 2023;44(47):4913–4924. DOI: 10.1093/eurheartj/ehad736